Importance Personalized medicine based on tumor profiling and identification of actionable
genomic alterations is pivotal in cancer management. Although tissue biopsy is still …

Simple Summary An important advance in the diagnostic and surveillance toolbox for
oncologists is circulating tumor DNA (ctDNA). This technology can detect microscopic levels …

BACKGROUND Targeted therapies have markedly changed the treatment of cancer over
the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a …

Tumor DNA contains specific somatic alterations that are crucial for the diagnosis and
treatment of cancer. Due to the spatial and temporal intra-tumor heterogeneity, multi …

Liquid biopsies appear to be a reliable alternative to conventional biopsies that can provide
both precise molecular data useful for improving the clinical management of lung cancer …

The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …

High-quality genomic analysis is critical for personalized pharmacotherapy in patients with
cancer. Tumor-specific genomic alterations can be identified in cell-free DNA (cfDNA) from …

Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from
human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and …

Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is an emerging non-
invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis …

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …